It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Moderna's updated Spikevax shot includes 25 µg of spike protein mRNA from BA.4/BA.5 and 25 µg from the original strain of SARS-CoV-2, and has been authorised for the over-18s. It has also been ...

On the economic data front, investors will focus on U.S. Wholesale Inventories data, which is set to be released in a couple of hours. Economists expect the preliminary December figure to be +0.2% m/m ...

A revolutionary personalized cancer vaccine developed by Russia’s Gamaleya Research Institute of Epidemiology and ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...